The identification and chromatographic separation of a new highly analogous impurity of the active pharmaceutical ingredient icatibant
Open Access
- 1 April 2019
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 132, 121-124
Abstract
No abstract availableKeywords
Funding Information
- Fresenius Kabi Austria GmbH
This publication has 18 references indexed in Scilit:
- Peptide therapeutics: current status and future directionsDrug Discovery Today, 2015
- Related impurities in peptide medicinesJournal of Pharmaceutical and Biomedical Analysis, 2014
- The Future of Peptide‐based DrugsChemical Biology & Drug Design, 2012
- Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary AngioedemaNew England Journal of Medicine, 2010
- The Recombinant Amyloid-β Peptide Aβ1–42 Aggregates Faster and Is More Neurotoxic than Synthetic Aβ1–42Journal of Molecular Biology, 2010
- Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)Journal of Allergy and Clinical Immunology, 2007
- Practical protocols for stepwise solid‐phase synthesis of cysteine‐containing peptidesChemical Biology & Drug Design, 2002
- Quality Control of Peptide Drugs. Chiral Amino Acid Analysis versus Standard for Icatibant AcetateArchiv der Pharmazie, 1995
- Hoe 140 a new potent and long acting bradykinin‐antagonist:in vitrostudiesBritish Journal of Pharmacology, 1991
- Hereditary angioneurotic edemaJournal of Allergy, 1962